Doxy-PEP Implementation Guide for Clinicians



Doxycycline used as post exposure prophylaxis (Doxy-PEP) is a new STI prevention tool proven to reduce bacterial STIs in some populations. Factors associated with STI acquisition include: prior STIs, condomless sex with multiple partners, partners with bacterial STIs, substance use, sex in group settings, or transactional sex.

NYS AIDS Institute Clinical Guidelines Program Doxy-PEP Recommendations

Candidates for Doxy-PEP¹

Persons with syphilis, gonorrhea or chlamydia in the past year² or high likelihood for acquisition of a bacterial STI³ MSM and TGW who have sex with men² (AMAB who have sex with AMAB persons)

Men who have sex with women³ (AMAB who have sex with AFAB persons)

Cisgender women and transgender men⁴ (AFAB with any sex partners)

Recommend

Consider Case By Case

Insufficient Data

MSM: Men who have sex with men; TGW: Transgender women; AMAB: Assigned male at birth; AFAB: Assigned female at birth

Doxy-PEP is not 100% effective and does not protect against all STIs.

Prescribing

Drug/Dose: Doxycycline (any form) 200 mg orally x1, taken ideally ≤24 hours but no later than 72 hours after exposure

Supply: Individualize #doses dispensed to last until next visit (30-90 days)

Precautions: Photosensitivity, esophageal injury, drug-drug interactions, contraindicated in pregnancy, do not exceed 200 mg in a 24 hour period

Initiation and Maintenance

Labs:

- HIV/STI screening every 3 months (including syphilis, gonorrhea and chlamydia at all sites of exposure)
- HBV screening at start, HCV screening at least annually

Other Sexual Health Services:

- HIV/STI prevention counseling
- HIV PrEP or HIV treatment
- Immunizations as indicated

Incident STIs and Exposures On Doxy-Pep

- Treat incident STIs per CDC STI Treatment Guidelines
- If exposed to early syphilis within prior 90 days, test and treat empirically regardless of doxy-PEP use
- If exposed to gonorrhea or chlamydia, can offer testing (treat if positive) or treat empirically

Suggested Billing Codes

- Z20.2 STI contact/exposure
- Z11.3 STI screening
- Z70.8 Other Sex Counseling
- Z20.9 Contact to unspecified communicable disease

Resources

For Clinical Questions: CEI Line 1-866-637-2342

For more information, see the full NYS AIDS Institute Doxy-PEP Guideline

Use Hyperlink or Scan QR Code



¹ A shared decision making approach is recommended. Include assessment of sexual history, risk of STI acquisition, and potential benefits/risks of Doxy-PEP use.

² Clinical trials showed significant reduction in bacterial STIs in this population who had a history of syphilis, gonorrhea or chlamydia in the past year.

³ These populations were not included in clinical trials but may benefit from the use of Doxy-PEP.

⁴ Clinical trial showed no impact of Doxy-PEP on incident STIs in cisgender women. Some data suggest adherence to medication may have impacted results.